Graves' disease
Also known as: toxic diffuse goiter
Medically reviewed by Hormone Journal Editorial Team · Last reviewed 2026-05-22
Graves' disease is the most common cause of hyperthyroidism, accounting for 60–80% of cases, and affects roughly 1 in 100 people — women 5–10 times more often than men.
What it is
Graves' disease is the most common cause of hyperthyroidism, responsible for 60–80% of all hyperthyroid cases, and affects approximately 1 in 100 people — women 5–10 times more often than men. Also called toxic diffuse goiter, Graves' disease is an autoimmune condition in which the immune system produces abnormal antibodies called thyroid-stimulating immunoglobulins (TSI) that bind to and continuously activate the TSH receptor on thyroid cells, driving unregulated overproduction of thyroid hormones T3 and T4. It most commonly presents between ages 20 and 50, though it can occur at any age.
What sets Graves' disease apart from other causes of hyperthyroidism is its capacity to affect organs beyond the thyroid. About 25% of people with Graves' disease develop Graves' orbitopathy (also called thyroid eye disease), which causes eye bulging, eyelid retraction, and in severe cases vision loss. A small subset develop pretibial myxedema — thickened, reddish skin on the lower legs. These extrathyroidal features do not occur in other forms of hyperthyroidism.
In Canada, thyroid conditions are among the most common endocrine disorders managed in primary care. Diagnosis and initial management typically occur through a family physician or internist, with specialist referral to an endocrinologist for complex cases, pregnancy, or when definitive therapy is being considered. Testing through LifeLabs or Dynacare includes TSH, free T4, free T3, and TSH receptor antibody (TRAb) panels.
Causes and mechanism
Graves' disease arises from a combination of genetic susceptibility and environmental triggers. The central mechanism involves TSI antibodies that mimic TSH, binding to TSH receptors on thyroid follicular cells and stimulating continuous hormone production outside the normal feedback loop.
Key contributing factors include:
- Genetic predisposition: Graves' disease clusters in families and is associated with specific HLA gene variants. Concordance is higher in identical twins than fraternal twins, confirming a heritable component.
- Female sex: The strong female predominance is linked to sex hormone effects on immune regulation; lifetime risk is approximately 3% in women versus 0.5% in men.
- Stress: Significant physical or psychological stress is a recognized trigger for onset and relapse.
- Pregnancy and postpartum: Immune shifts during and after pregnancy can precipitate or worsen the condition.
- Smoking: A strong independent risk factor specifically for Graves' orbitopathy.
- Iodine excess: High iodine intake can trigger hyperthyroidism in genetically predisposed individuals.
- Coexisting autoimmune disease: People with type 1 diabetes, Addison's disease, or vitiligo carry elevated risk.
Symptoms and diagnosis
Graves' disease produces the full spectrum of hyperthyroid symptoms alongside its unique autoimmune features.
General hyperthyroid symptoms:
- Rapid or irregular heartbeat (palpitations; atrial fibrillation in severe cases)
- Unintentional weight loss despite increased appetite
- Heat intolerance and increased sweating
- Fine tremor of the hands
- Fatigue and proximal muscle weakness
- Anxiety, irritability, and emotional instability
- Insomnia
- Frequent bowel movements or diarrhea
- Irregular or absent menstrual periods
- Reduced libido or erectile dysfunction
Graves'-specific features:
- Diffuse goiter — smooth, symmetrical thyroid enlargement visible at the front of the neck
- Graves' orbitopathy — eye bulging (proptosis), eyelid retraction, gritty eye sensation, double vision, or vision loss in severe cases
- Pretibial myxedema — thickened reddish skin on the lower legs (uncommon)
Diagnostic workup:
| Test | Expected finding in Graves' disease |
|---|---|
| TSH | Suppressed (very low or undetectable) |
| Free T4 and free T3 | Elevated |
| TSH receptor antibodies (TRAb / TSI) | Positive — key differentiator from other hyperthyroid causes |
| Thyroid ultrasound | Diffusely enlarged, hypervascular gland |
| Radioactive iodine uptake scan | Diffusely increased uptake across the whole gland |
TRAb positivity distinguishes Graves' disease from thyroiditis and toxic nodular goiter, which do not produce these antibodies.
Treatment options
Three evidence-based approaches exist. Choice depends on disease severity, patient age, pregnancy status, goiter size, and whether orbitopathy is present.
Anti-thyroid medications Methimazole blocks thyroid hormone synthesis and is the preferred first-line agent for most patients. A standard course runs 12–18 months; remission is achieved in approximately 30–50% of patients. Propylthiouracil (PTU) is preferred in the first trimester of pregnancy because methimazole carries a higher teratogenic risk in early gestation. Beta-blockers (propranolol, atenolol) relieve palpitations, tremor, and anxiety while hormone levels normalize but do not treat the underlying disease.
Radioactive iodine (RAI) therapy An oral dose of iodine-131 selectively destroys thyroid tissue. It is highly effective and widely used. Most patients become permanently hypothyroid afterward and require lifelong levothyroxine replacement. RAI is contraindicated in pregnancy and should be used cautiously in patients with active or moderate-to-severe Graves' orbitopathy, as it can worsen eye disease.
Thyroid surgery (thyroidectomy) Total or near-total thyroidectomy offers rapid, definitive resolution. It is preferred for patients with large goiters, coexisting thyroid nodules, significant orbitopathy, or those who cannot tolerate medications. Lifelong levothyroxine replacement follows.
Managing Graves' orbitopathy
- Selenium supplementation (200 mcg/day for 6 months): evidence supports benefit in mild-to-moderate eye disease
- Intravenous methylprednisolone: for moderate-to-severe orbitopathy
- Teprotumumab: a targeted biologic approved for moderate-to-severe thyroid eye disease
- Orbital decompression surgery: for severe proptosis or vision-threatening disease
When to see a clinician in Canada
See a physician if you notice unexplained weight loss despite a normal or increased appetite, a rapid or irregular heartbeat, persistent hand tremor, visible neck swelling, or eye changes such as bulging, persistent irritation, or double vision. Significant anxiety, heat intolerance, or excessive sweating without a clear cause also warrants assessment.
Seek urgent care or go to an emergency department if you develop a very rapid heart rate, high fever, and extreme agitation or confusion simultaneously. These signs may indicate thyroid storm — a rare but life-threatening complication of severe untreated hyperthyroidism that carries significant mortality without prompt treatment.
In Canada, initial testing (TSH, free T4, TRAb) is available through provincial laboratory networks including LifeLabs and Dynacare and is covered under provincial health insurance. Canadians seeking virtual assessment before an in-person referral can access licensed physicians through platforms such as Maple, Felix, or Cleo, though specialist endocrinology referral is typically required for definitive therapy decisions.
Limitations and open questions
Research is still emerging on several aspects of Graves' disease management. The optimal duration of anti-thyroid drug therapy and the best predictors of durable remission remain debated; current remission rates of 30–50% after a standard course mean that many patients relapse and require a second treatment decision. The role of extended low-dose methimazole beyond 18 months is under active investigation. For Graves' orbitopathy, teprotumumab shows strong efficacy data but long-term safety data and its availability and coverage under Canadian provincial drug benefit programs are not yet fully established — Health Canada approved teprotumumab (Tepezza) in 2022, but formulary listing varies by province. The precise mechanisms linking psychological stress to disease onset and relapse are not fully characterized. Evidence on optimal management of Graves' disease in transgender and non-binary patients on gender-affirming hormone therapy is limited.
FAQs
Does Graves' disease go away on its own?
Graves' disease can go into remission, but this is not reliably predictable without treatment. Anti-thyroid medication induces remission in approximately 30–50% of patients after a standard 12–18 month course. Remission is more likely in people with small goiters, mild hyperthyroidism, and low or negative antibody levels at the end of treatment. Relapse is common — particularly in the first year after stopping medication — which is why regular follow-up with a physician is essential even after apparent remission.
What is the difference between Graves' disease and Hashimoto's thyroiditis?
Both are autoimmune thyroid conditions, but they have opposite effects on thyroid function. Graves' disease causes the thyroid to be overactive (hyperthyroidism) through stimulating TSI antibodies that drive excess hormone production. Hashimoto's thyroiditis causes the thyroid to become underactive (hypothyroidism) as immune-mediated destruction gradually reduces hormone output. Both conditions can coexist in the same person at different points in time, and a small number of patients transition between the two states — a phenomenon sometimes called Hashitoxicosis.
Can Graves' disease affect pregnancy?
Yes, and uncontrolled hyperthyroidism during pregnancy carries serious risks including miscarriage, preterm birth, and low birth weight. Graves' antibodies (TRAb) can cross the placenta and, in rare cases, cause fetal or neonatal hyperthyroidism. Management requires close collaboration between an endocrinologist and obstetrician, using the lowest effective dose of anti-thyroid medication — PTU is preferred in the first trimester, then methimazole from the second trimester onward — with regular monitoring of both maternal and fetal thyroid function throughout.
Will I need to take medication for life after treatment for Graves' disease?
It depends on which treatment is chosen. With anti-thyroid medication alone, roughly 30–50% of patients achieve lasting remission and do not need ongoing thyroid treatment. If radioactive iodine or thyroid surgery is used, the result is typically permanent hypothyroidism, which requires lifelong once-daily levothyroxine replacement. Many patients and clinicians find lifelong levothyroxine preferable to the uncertainty of recurrent hyperthyroidism, as it is well tolerated and straightforward to manage.
Is treatment for Graves' disease covered in Canada?
Diagnostic testing — including TSH, free T4, and TSH receptor antibody (TRAb) panels — is covered under provincial health insurance across Canada and is available through laboratory networks such as LifeLabs and Dynacare. Anti-thyroid medications (methimazole, PTU) and levothyroxine are listed on most provincial formularies, though coverage details vary by province and individual drug benefit plan. Radioactive iodine therapy is available at major Canadian hospital centres and is generally covered. Teprotumumab (Tepezza) for Graves' orbitopathy received Health Canada approval in 2022 but provincial formulary coverage remains inconsistent — patients should check with their provincial drug benefit program.
Sources
- Ross DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism. Thyroid. 2016;26(10):1343–1421.
- Bartalena L, et al. 2021 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism. European Thyroid Journal. 2021;10(6):600–652.
- Smith TJ, Hegedüs L. Graves' Disease. New England Journal of Medicine. 2016;375(16):1552–1565.
- Pokhrel B, Bhusal K. Graves Disease. StatPearls. NIH/NCBI Bookshelf. Updated June 2023.
- Anastasopoulou C, Correa R. Diffuse Toxic Goiter. StatPearls. NIH/NCBI Bookshelf. Updated February 2026.
- Mayo Clinic. Graves' Disease — Symptoms and Causes.